Elsevier

Current Opinion in Pharmacology

Volume 41, August 2018, Pages vii-ix
Current Opinion in Pharmacology

Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity

https://doi.org/10.1016/j.coph.2018.07.013Get rights and content

Section snippets

Ed Lavelle graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth. He carried our postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants. This was followed by further postdoctoral positions at the Rowett Research Institute and Trinity College Dublin (TCD) on vaccine adjuvants and immunomodulators. He was appointed as a lecturer in 2004, associate Professor in 2012 and Professor in

References (10)

  • D.S. Vinay et al.

    Immune evasion in cancer: mechanistic basis and therapeutic strategies

    Semin Cancer Biol

    (2015)
  • M. Domenech de Cellès et al.

    The impact of past vaccination coverage and immunity on pertussis resurgence

    Sci Transl Med

    (2018)
  • J.M. Warfel et al.

    Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model

    Proc Natl Acad Sci USA

    (2014)
  • E. De Gregorio et al.

    From empiricism to rational design: a personal perspective of the evolution of vaccine development

    Nat Rev Immunol

    (2014)
  • V.N. Petrova et al.

    The evolution of seasonal influenza viruses

    Nat Rev Microbiol

    (2018)
There are more references available in the full text version of this article.

Cited by (7)

View all citing articles on Scopus

Ed Lavelle graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth. He carried our postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants. This was followed by further postdoctoral positions at the Rowett Research Institute and Trinity College Dublin (TCD) on vaccine adjuvants and immunomodulators. He was appointed as a lecturer in 2004, associate Professor in 2012 and Professor in Immunology at TCD in 2015. He is currently Head of the School of Biochemistry and Immunology at TCD and President of the Irish Society for Immunology. His main research area is the mechanism by which particulate adjuvants modulate innate and adaptive immune responses with a strong focus on translating this work to develop novel adjuvants for injectable and mucosal vaccines.

James McLachlan obtained his B.A. in Biology from Appalachian State University and then received a PhD from Duke University where he studied the role of mast cells in the initiation of the adaptive immune response. He went on to perform postdoctoral research at the University of Minnesota – Twin Cities, exploring the intricacies of helper T cell responses in non-lymphoid tissues. He joined the faculty of the Tulane University School of Medicine in the Department of Microbiology and Immunology in 2009 as an Assistant Professor and was promoted to Associate Professor in 2015. His group is interested in the immunological mechanisms of vaccine efficacy and vaccine design as well as understanding cellular immune responses to intracellular bacterial infections.

View full text